BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nasulin intranasal insulin: Preliminary Phase IIa data

Preliminary data from a double-blind, U.S. Phase IIa trial in 94 patients showed that inhaled Nasulin in combination with basal insulin and oral diabetes agents missed the primary endpoint of significantly increasing the mean proportion of time spent in euglycemia from baseline as assessed by CGM vs. placebo (p=0.20). Nasulin also missed the secondary endpoints of a...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >